Harvest One Share Price, page-2356

Key findings of the trial

• Satipharm’s CBD capsules significantly reduced monthly seizures in treatment-resistant children when added to current medications. The median reduction was -82% in the 12-week treatment period
• 9/16 patients (56%) who started the treatment had a reduction of at least 50% in total number of seizures during the entire treatment period, compared to observation
• Following 12 weeks of treatment, 8/11 patients (73%) were rated as “very much improved/improved” in overall condition on the Caregiver Global Impression of Improvement scale and 9/11 patients (82%) were rated as “very much reduced/reduced” on that scale
• A mean 73.4% reduction from baseline monthly seizure frequencies was observed
• Two patients fully seizure-free within 5 weeks of treatment
• An additional seven patients reported >50% seizure frequency reduction